{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97"}]}],"title":"Percentage of Patients Without Progression at 12 m"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92"}]}],"title":"Percentage of Patients Without Progression at 24 m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"The Progression Free Survival (PFS) rate will be determined at 12 and 24 months post treatment.\n\nProgressive Disease (PD) is defined as an increase of greater than or equal to 25% from lowest response level in serum M-component and/ or urine M-component and/ or the difference between involved or uninvolved SFLC levels and/ or bone marrow % plasma cells. PD may also be the development of new bone lesions or soft tissue plasmacytomas or the increase in size of existing lesions. PD may also be the development of hypercalcemia.","groups":[{"description":"Carfilzomib will be administered as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).\n\nLenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.\n\nDexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.","id":"OG000","title":"Carfilzomib, Lenalidomide w/Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 Months and 24 Months Post Treatment","title":"The Percentage of Patients Alive Without Progression","type":"SECONDARY","unitOfMeasure":"percentage of patients"}